Larimar Therapeutics, Inc.
LRMR
$3.58
-$0.31-7.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.25% | 8.91% | 11.48% | 23.31% | 22.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.79% | 89.50% | 64.86% | 107.15% | 117.66% |
| Operating Income | -89.79% | -89.50% | -64.86% | -107.15% | -117.66% |
| Income Before Tax | -105.54% | -103.79% | -71.05% | -111.26% | -118.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -105.54% | -103.79% | -71.05% | -111.26% | -118.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.54% | -103.79% | -71.05% | -111.26% | -118.15% |
| EBIT | -89.79% | -89.50% | -64.86% | -107.15% | -117.66% |
| EBITDA | -90.07% | -89.87% | -65.18% | -107.78% | -118.52% |
| EPS Basic | -69.03% | -67.41% | -40.03% | -54.29% | -55.30% |
| Normalized Basic EPS | -69.03% | -67.39% | -40.02% | -54.30% | -55.32% |
| EPS Diluted | -69.03% | -67.41% | -40.03% | -54.29% | -55.30% |
| Normalized Diluted EPS | -69.03% | -67.39% | -40.02% | -54.30% | -55.32% |
| Average Basic Shares Outstanding | 18.99% | 20.02% | 24.59% | 37.85% | 39.50% |
| Average Diluted Shares Outstanding | 18.99% | 20.02% | 24.59% | 37.85% | 39.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |